title: [Is chemotherapy still a valid option for oncogene-addicted lung cancer? Yes].
abstract: With the emergence of molecular targeted therapies in the management of non-small cell lung cancer, the role of conventional chemotherapy can be questioned. This article presents the key arguments for the use of cytotoxics in presence of a targetable alteration.
authors.affiliation: Gustave-Roussy, Villejuif, Université Paris Sud, Paris, France. Electronic address: benjamin.besse@gustaveroussy.fr.
authors.forename: Benjamin
authors.initials: B
authors.lastname: Besse
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D018773:Genes, erbB-1 / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D058990:Molecular Targeted Therapy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: Cancer bronchique; Chemotherapy; Chimiothérapie; Lung cancer; Molecular targeted therapies; Thérapies moléculaires ciblées